Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV)

Affiliations

• ¹ Université de Paris, AP-HP, Hôpital Saint-Louis Inserm, Centre d'Investigations Cliniques, INSERM Paris France.
• ² AOP Orphan Pharmaceuticals GmbH Vienna Austria.
• ³ Medical University of Plovdiv Plovdiv Bulgaria.
• ⁴ Teaching Unit of the Hematology Department University Hospital in Krakow Krakow Poland.
• ⁵ Multiprofile Hospital for Active Treatment "Sveta Marina", Clinical Hematology Clinic Varna Bulgaria.
• ⁶ Department of Internal Medicine II Kaposi Mor County Teaching Hospital Kaposvar Hungary.
• ⁷ Department of Clinical Hematology University Hospital Hradec Kralove Hradec Kralove Czech Republic.
• ⁸ Faculty of Medicine, Department of Hematology University of Debrecen Debrecen Hungary.
• ⁹ Department of Hematology Cherkasy Regional Oncology Centre, Regional Treatment and Diagnostics Haematology Centre Cherkasy Ukraine.
• ¹⁰ First Department of Internal Medicine Multiprofile Hospital for Active Treatment - HristoBotev Vratsa Bulgaria.
• ¹¹ University Hospital Brno, Clinic of Internal Medicine - Hematology and Oncology Brno Czech Republic.
• ¹² Department of Hematology Yaroslavl Regional Clinical Hospital Yaroslavl Russia.
• ¹³ Department of Hematology Zealand University Hospital, University of Copenhagen Roskilde Denmark.
• ¹⁴ Department of Laboratory Medicine Medical University of Vienna Vienna Austria.
• ¹⁵ Department of Internal Medicine I, Division of Hematology and Blood Coagulation Medical University Vienna Vienna Austria.